



**EFFECTIVE DATE:** 12|18|2012  
**POLICY LAST UPDATED:** 07|07|2021

## OVERVIEW

Neural therapy involves the injection of a local anesthetic such as procaine or lidocaine into various tissues such as scars, trigger points, acupuncture points, tendon and ligament insertions, peripheral nerves, autonomic ganglia, the epidural space, and other tissues to treat chronic pain. Neural therapy has been proposed for other chronic illness syndromes such as allergies, infertility, tinnitus, depression, and chronic bowel problems. When the anesthetic agent is injected into traditional acupuncture points, this treatment may be called neural acupuncture.

## MEDICAL CRITERIA

Not applicable

## PRIOR AUTHORIZATION

Not applicable

## POLICY STATEMENT

### Medicare Advantage Plans

Neural Therapy is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

### Commercial Products

Neural therapy is considered not medically necessary for all indications as the evidence is insufficient to determine the effects of the technology on health outcomes.

## COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

## BACKGROUND

The practice of neural therapy is based on the belief that energy flows freely through the body. It is proposed that injury, disease, malnutrition, stress, and scar tissue disrupt this flow, creating disturbances in the electrochemical function of tissues and energy imbalances called “interference fields.” Injection of a local anesthetic is believed to reestablish the normal resting potential of nerves and flow of energy. Alternative theories include fascial continuity, the ground (matrix) system, and the lymphatic system.

There is a strong focus on treatment of the autonomic nervous system, and injections may be given at a location other than the source of the pain or location of an injury. Neural therapy is promoted mainly to relieve chronic pain. It has also been proposed to be helpful for allergies, hay fever, headaches, arthritis, asthma, hormone imbalances, libido, infertility, tinnitus, chronic bowel problems, sports or muscle injuries, gallbladder, heart, kidney, or liver disease, dizziness, depression, menstrual cramps, and skin and circulation problems.

Neural therapy should be distinguished from the use of peripherally injected anesthetic agents for nerve blocks or local anesthesia. The site of the injection for neural therapy may be located far from the source of

the pain or injury. The length of treatment can vary from one session to a series of sessions over a period of weeks or months.

For individuals who have chronic pain or illness (eg, pain, allergies, hay fever, headaches, arthritis, asthma, hormone imbalances, libido, infertility, tinnitus, chronic bowel problems, sports or muscle injuries, gallbladder, heart, kidney, or liver disease, dizziness, depression, menstrual cramps, skin and circulation problems) who receive neural therapy, the evidence includes small randomized trials and a large case series. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. There are few English-language reports assessing the use of neural therapy for pain, and the available studies have methodologic limitations that preclude conclusions on efficacy. The evidence is insufficient to determine the effects of the technology on health outcomes.

## **CODING**

### **Medicare Advantage Plan and Commercial Products**

There are no specific HCPCS or CPT codes for these local anesthetics when injected in this fashion. The procedure would be reported using an unlisted CPT code.

## **RELATED POLICIES**

Not applicable

## **PUBLISHED**

Provider Update, Sep 2021

Provider Update, June 2020

Provider Update, July 2019

Provider Update, August 2018

Provider Update, June 2017

## **REFERENCES**

1. Frank BL. Neural therapy. *Phys Med Rehabil Clin N Am*. Aug 1999; 10(3): 573-82, viii. PMID 10516978
2. Altinbilek T, Terzi R, Basaran A, et al. Evaluation of the effects of neural therapy in patients diagnosed with fibromyalgia. *Turk J Phys Med Rehabil*. Mar 2019; 65(1): 1-8. PMID 31453538
3. Nazlikul H, Ural FG, Ozturk GT, et al. Evaluation of neural therapy effect in patients with piriformis syndrome. *J Back Musculoskelet Rehabil*. 2018; 31(6): 1105-1110. PMID 30010101
4. Montenegro ML, Braz CA, Rosa-e-Silva JC, et al. Anaesthetic injection versus ischemic compression for the pain relief of abdominal wall trigger points in women with chronic pelvic pain. *BMC Anesthesiol*. Dec 01 2015; 15: 175. PMID 26628263
5. Balevi Batur E, Atan T. Neural therapy for fibromyalgia: myth or improving quality of life?. *Int J Clin Pract*. Sep 21 2020; e13719. PMID 32955788
6. Egli S, Pfister M, Ludin SM, et al. Long-term results of therapeutic local anesthesia (neural therapy) in 280 referred refractory chronic pain patients. *BMC Complement Altern Med*. Jun 27 2015; 15: 200. PMID 26115657
7. Atalay NS, Sahin F, Atalay A, et al. Comparison of efficacy of neural therapy and physical therapy in chronic low back pain. *Afr J Tradit Complement Altern Med*. 2013; 10(3): 431-5. PMID 24146471
8. American Association of Orthopaedic Medicine. Neural Therapy. 2013; <http://www.aaomed.org/Neural-therapy>. Accessed September, 2020.
9. Learman LA, McHugh KW. Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218. *Obstet Gynecol*. Mar 2020; 135(3): e98-e109. PMID 32080051
10. Yadav V, Bever C, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. *Neurology*. Mar 25 2014; 82(12): 1083-92. PMID 24663230
11. Gibson RG, Gibson SL. Neural therapy in the treatment of multiple sclerosis. *J Altern Complement Med*. Dec 1999; 5(6): 543-52. PMID 10630348

12. North American Spine Society. Diagnosis and treatment of low back pain. 2020. Accessed September 15, 2020.

13. Garvey TA, Marks MR, Wiesel SW. A prospective, randomized, double-blind evaluation of trigger-point injection therapy for low-back pain. *Spine (Phila Pa 1976)*. Sep 1989; 14(9): 962-4. PMID 2528826

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

